64 related articles for article (PubMed ID: 21908103)
41. HYNIC and DOMA conjugated radiolabeled bombesin analogs as receptor-targeted probes for scintigraphic detection of breast tumor.
De K; Mukherjee D; Sinha S; Ganguly S
EJNMMI Res; 2019 Mar; 9(1):25. PubMed ID: 30887136
[TBL] [Abstract][Full Text] [Related]
42. Neuromedin B Induces Acute Itch in Mice via the Activation of Peripheral Sensory Neurons.
Ehling S; Fukuyama T; Ko MC; Olivry T; Bäumer W
Acta Derm Venereol; 2019 May; 99(6):587-893. PubMed ID: 30734045
[TBL] [Abstract][Full Text] [Related]
43. A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.
Moreno P; Mantey SA; Lee SH; Ramos-Álvarez I; Moody TW; Jensen RT
Peptides; 2018 Mar; 101():213-226. PubMed ID: 29410320
[TBL] [Abstract][Full Text] [Related]
44. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.
Khan M; Huang T; Lin CY; Wu J; Fan BM; Bian ZX
Oncotarget; 2017 Nov; 8(61):104615-104637. PubMed ID: 29262666
[TBL] [Abstract][Full Text] [Related]
45. Neuromedin B Restores Erectile Function by Protecting the Cavernous Body and the Nitrergic Nerves from Injury in a Diabetic Rat Model.
Nishimatsu H; Suzuki E; Saito Y; Niimi A; Nomiya A; Yamada D; Homma Y
PLoS One; 2015; 10(7):e0133874. PubMed ID: 26207818
[TBL] [Abstract][Full Text] [Related]
46. Hypoxia regulates the expression of the neuromedin B receptor through a mechanism dependent on hypoxia-inducible factor-1α.
Park HJ; Kim MK; Kim SR; Bae SK; Bae MK
PLoS One; 2013; 8(12):e82868. PubMed ID: 24349381
[TBL] [Abstract][Full Text] [Related]
47. Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.
Jaeger M; Nör C; de Farias CB; Abujamra AL; Schwartsmann G; Brunetto AL; Roesler R
Childs Nerv Syst; 2013 Dec; 29(12):2145-50. PubMed ID: 24092425
[TBL] [Abstract][Full Text] [Related]
48. Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER.
Gigoux V; Fourmy D
Front Endocrinol (Lausanne); 2013; 4():50. PubMed ID: 23641235
[TBL] [Abstract][Full Text] [Related]
49. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
50. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
51. Identification of genes regulated by the EWS/NR4A3 fusion protein in extraskeletal myxoid chondrosarcoma.
Filion C; Labelle Y
Tumour Biol; 2012 Oct; 33(5):1599-605. PubMed ID: 22592656
[TBL] [Abstract][Full Text] [Related]
52. Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells.
Park HJ; Kim MK; Choi KS; Jeong JW; Bae SK; Kim HJ; Bae MK
Int J Oncol; 2016 Sep; 49(3):934-42. PubMed ID: 27571778
[TBL] [Abstract][Full Text] [Related]
53. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
54. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer.
Guha S; Eibl G; Kisfalvi K; Fan RS; Burdick M; Reber H; Hines OJ; Strieter R; Rozengurt E
Cancer Res; 2005 Apr; 65(7):2738-45. PubMed ID: 15805273
[TBL] [Abstract][Full Text] [Related]
55. Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo.
Park HJ; Kim SR; Kim MK; Choi KS; Jang HO; Yun I; Bae SK; Bae MK
Cancer Lett; 2011 Dec; 312(1):117-27. PubMed ID: 21908103
[TBL] [Abstract][Full Text] [Related]
56. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
57. Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Ryan RR; Katsuno T; Mantey SA; Pradhan TK; Weber HC; Coy DH; Battey JF; Jensen RT
J Pharmacol Exp Ther; 1999 Sep; 290(3):1202-11. PubMed ID: 10454496
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
